Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1985 Jul;28(1):33–36. doi: 10.1128/aac.28.1.33

Ceftazidime versus tobramycin-ticarcillin in the treatment of pneumonia and bacteremia.

L A Cone, D R Woodard, D S Stoltzman, R G Byrd
PMCID: PMC176304  PMID: 3899005

Abstract

A prospective, randomized study was undertaken to compare the efficacy and safety of ceftazidime with those of a combination of ticarcillin and tobramycin in the treatment of 40 nonneutropenic patients with pneumonia or bacteremia. Altogether, 93% of the patients receiving ceftazidime for pneumonia were cured, and 87% of those with bacteremia responded favorably. Of the subjects who were treated with ticarcillin and tobramycin ceftazidime developed significant superinfection, and one individual treated with the aminoglycoside and carboxypenicillin developed reversible azotemia. Ceftazidime appears to be as efficacious as the ticarcillin-tobramycin combination and is probably safer with regard to oto-and nephrotoxicity; however, superinfections did occur more frequently in the group treated with ceftazidime.

Full text

PDF
33

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baker R. L., Fass R. J. Correlation of in vitro activities of cephalothin and ceftazidime with their efficacies in the treatment of Staphylococcus aureus endocarditis in rabbits. Antimicrob Agents Chemother. 1984 Aug;26(2):231–234. doi: 10.1128/aac.26.2.231. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Cone L. A. A survey of prospective, controlled clinical trials of gentamicin, tobramycin, amikacin, and netilmicin. Clin Ther. 1982;5(2):155–162. [PubMed] [Google Scholar]
  3. Eliopoulos G. M., Moellering R. C., Jr Antibiotic synergism and antimicrobial combinations in clinical infections. Rev Infect Dis. 1982 Mar-Apr;4(2):282–293. doi: 10.1093/clinids/4.2.282. [DOI] [PubMed] [Google Scholar]
  4. Friis H., Hoffmann S., Hansen M., Hansen M. M., Justesen T., Nissen N. I. Cefotaxime versus ampicillin, methicillin and netilmicin in combination for treatment of febrile episodes in patients with haematologic malignancy. Acta Med Scand. 1983;213(5):345–349. doi: 10.1111/j.0954-6820.1983.tb03749.x. [DOI] [PubMed] [Google Scholar]
  5. Gozzard D. I., Geddes A. M., Farrell I. D., Eykyn S. J., Phillips I., Wise R., Brown R. M. Ceftazidime--a new extended-spectrum cephalosporin. Lancet. 1982 May 22;1(8282):1152–1156. doi: 10.1016/s0140-6736(82)92228-0. [DOI] [PubMed] [Google Scholar]
  6. Hahn D. M., Schimpff S. C., Young V. M., Fortner C. L., Standiford H. C., Wiernik P. H. Amikacin and cephalothin: empiric regimen for granulocytopenic cancer patients. Antimicrob Agents Chemother. 1977 Nov;12(5):618–624. doi: 10.1128/aac.12.5.618. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Kahlmeter G., Dahlager J. I. Aminoglycoside toxicity - a review of clinical studies published between 1975 and 1982. J Antimicrob Chemother. 1984 Jan;13 (Suppl A):9–22. doi: 10.1093/jac/13.suppl_a.9. [DOI] [PubMed] [Google Scholar]
  8. Klastersky J., Cappel R., Daneau D. Therapy with carbenicillin and gentamicin for patients with cancer and severe infections caused by gram-negative rods. Cancer. 1973 Feb;31(2):331–336. doi: 10.1002/1097-0142(197302)31:2<331::aid-cncr2820310210>3.0.co;2-s. [DOI] [PubMed] [Google Scholar]
  9. Klastersky J., Debusscher L., Weerts-Ruhl D., Prevost J. M. Carbenicillin, cefazolin, and amikacin as an empiric therapy for febrile granulocytopenic cancer patients. Cancer Treat Rep. 1977 Nov;61(8):1433–1439. [PubMed] [Google Scholar]
  10. Klastersky J., Hensgens C., Debusscher L. Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin. Antimicrob Agents Chemother. 1975 May;7(5):640–645. doi: 10.1128/aac.7.5.640. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Klastersky J. Treatment of severe infections in patients with cancer. The role of new acyl-penicillins. Arch Intern Med. 1982 Oct 25;142(11):1984–1987. [PubMed] [Google Scholar]
  12. Lerner A. M., Reyes M. P., Cone L. A., Blair D. C., Jansen W., Wright G. E., Lorber R. R. Randomised, controlled trial of the comparative efficacy, auditory toxicity, and nephrotoxicity of tobramycin and netilmicin. Lancet. 1983 May 21;1(8334):1123–1126. doi: 10.1016/s0140-6736(83)92864-7. [DOI] [PubMed] [Google Scholar]
  13. Moellering R. C., Jr Enterococcal infections in patients treated with moxalactam. Rev Infect Dis. 1982 Nov-Dec;4 (Suppl):S708–S711. doi: 10.1093/clinids/4.supplement_3.s708. [DOI] [PubMed] [Google Scholar]
  14. Neu H. C., Labthavikul P. Antibacterial activity and beta-lactamase stability of ceftazidime, an aminothiazolyl cephalosporin potentially active against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1982 Jan;21(1):11–18. doi: 10.1128/aac.21.1.11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Palmblad J., Lönnqvist B. Combination of amikacin and either ampicillin or cephalotin as initial treatment of febrile neutropenic patients. Acta Med Scand. 1982;212(6):379–384. doi: 10.1111/j.0954-6820.1982.tb03233.x. [DOI] [PubMed] [Google Scholar]
  16. Parry M. F., Neu H. C. A comparative study of ticarcillin plus tobramycin versus carbenicillin plus gentamicin for the treatment of serious infections due to gram-negative bacilli. Am J Med. 1978 Jun;64(6):961–966. doi: 10.1016/0002-9343(78)90450-3. [DOI] [PubMed] [Google Scholar]
  17. Pennington J. E., Reynolds H. Y., Carbone P. P. Pseudomonas pneumonia. A retrospective study of 36 cases. Am J Med. 1973 Aug;55(2):155–160. doi: 10.1016/0002-9343(73)90163-0. [DOI] [PubMed] [Google Scholar]
  18. Phair J. P., Bassaris H. P., Williams J. E., Metzger E. Bacteremic pneumonia due to gram-negative bacilli. Arch Intern Med. 1983 Nov;143(11):2147–2149. [PubMed] [Google Scholar]
  19. Pierce A. K., Sanford J. P. Aerobic gram-negative bacillary pneumonias. Am Rev Respir Dis. 1974 Nov;110(5):647–658. doi: 10.1164/arrd.1974.110.5.647. [DOI] [PubMed] [Google Scholar]
  20. Rahal J. J., Jr Antibiotic combinations: the clinical relevance of synergy and antagonism. Medicine (Baltimore) 1978 Mar;57(2):179–195. [PubMed] [Google Scholar]
  21. Rahal J. J., Jr Rationale for use of antimicrobial combinations in treatment of gram-negative infections. A review of recent reviews. Am J Med. 1983 Aug 29;75(2A):68–71. doi: 10.1016/0002-9343(83)90097-9. [DOI] [PubMed] [Google Scholar]
  22. Reyes M. P. The aerobic gram-negative bacillary pneumonias. Med Clin North Am. 1980 May;64(3):363–383. doi: 10.1016/s0025-7125(16)31598-x. [DOI] [PubMed] [Google Scholar]
  23. Sanders C. C., Sanders W. E., Jr Emergence of resistance during therapy with the newer beta-lactam antibiotics: role of inducible beta-lactamases and implications for the future. Rev Infect Dis. 1983 Jul-Aug;5(4):639–648. doi: 10.1093/clinids/5.4.639. [DOI] [PubMed] [Google Scholar]
  24. Schimpff S. C., Aisner J. Empiric antibiotic therapy. Cancer Treat Rep. 1978 May;62(5):673–680. [PubMed] [Google Scholar]
  25. Scully B. E., Neu H. C. The use of ceftizoxime in the treatment of critically ill patients infected with multiply antibiotic resistant bacteria. J Antimicrob Chemother. 1982 Nov;10 (Suppl 100):141–150. doi: 10.1093/jac/10.suppl_c.141. [DOI] [PubMed] [Google Scholar]
  26. Setia U., Serventi I., Lorenz P. Bacteremia in a long-term care facility. Spectrum and mortality. Arch Intern Med. 1984 Aug;144(8):1633–1635. [PubMed] [Google Scholar]
  27. Smith C. R., Baughman K. L., Edwards C. Q., Rogers J. F., Lietman P. S. Controlled comparison of amikacin and gentamicin. N Engl J Med. 1977 Feb 17;296(7):349–353. doi: 10.1056/NEJM197702172960701. [DOI] [PubMed] [Google Scholar]
  28. Wilson W. R., Henry N. K., Keys T. F., Anhalt J. P., Cockerill F. R., 3rd, Edson R. S., Geraci J. E., Hermans P. E., Muller S. M., Rosenblatt J. E. Empiric therapy with moxalactam alone in patients with bacteremia. Mayo Clin Proc. 1984 May;59(5):318–326. doi: 10.1016/s0025-6196(12)61427-x. [DOI] [PubMed] [Google Scholar]
  29. Yu V. L. Enterococcal superinfection and colonization after therapy with moxalactam, a new broad-spectrum antibiotic. Ann Intern Med. 1981 Jun;94(6):784–785. doi: 10.7326/0003-4819-94-6-784. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES